Rein Therapeutics, Inc. (RNTX) stock
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.00 (-0.31%)
Close on Nov 18, 2026Market cap $30.65MP/E –Yield 0.00%
Rein Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Rein Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$18.83M. For fiscal 2025 it was -$19.36M. The highest annual figure on record is -$11.71M in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$19.36M | – |
| FY2024 | Dec 31, 2024 | -$22.29M | – |
| FY2023 | Dec 31, 2023 | -$19.81M | – |
| FY2022 | Dec 31, 2022 | -$24.87M | – |
| FY2021 | Dec 31, 2021 | -$23.75M | – |
| FY2020 | Dec 31, 2020 | -$20.48M | – |
| FY2019 | Dec 31, 2019 | -$26.47M | – |
| FY2018 | Dec 31, 2018 | -$27.93M | – |
| FY2017 | Dec 31, 2017 | -$20.53M | – |
| FY2016 | Dec 31, 2016 | -$15.01M | – |
| FY2015 | Dec 31, 2015 | -$11.71M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.81M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.82M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.66M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.41M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.26M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.76M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.69M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.07M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.31M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.98M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.69M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.50M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.66M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.88M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.46M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.93M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.24M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.51M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.95M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.23M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.93M | – |
See a number that looks wrong?